Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hydroxypropyl Methyl Cellulose
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Teva Pharma (Thailand)
Deal Size : Undisclosed
Deal Type : Acquisition
Taiwan's Lotus Pharma acquires Teva Pharma Thailand, expanding footprint in Southeast Asia
Details : Lotus will gain access to Teva’s ophthalmic and respiratory portfolio, including NATEAR (hydroxypropyl methylcellulose) used as artificial tears to prevent conjunctival and corneal damage.
Product Name : Natear
Product Type : Carbohydrate
Upfront Cash : Undisclosed
June 06, 2024
Lead Product(s) : Hydroxypropyl Methyl Cellulose
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Teva Pharma (Thailand)
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Amarin
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership aims to distribute and commercialize Vazkepa (icosapent ethyl), approved and commercialized in a number of global markets, including the U.S. and European markets, across 10 countries, including nine in Southeast Asia and South Korea.
Product Name : Vazkepa
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 31, 2023
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Amarin
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Recipient : NRx Pharmaceuticals
Deal Size : $345.0 million
Deal Type : Collaboration
Details : The collaboration aims to develop and commercialize NRX-101, an fixed dose oral combination of D-cycloserine and lurasidone for treatment-resistant suicidal bipolar depression (S-TRBD). It is one of the first oral antidepressants targeting the NMDA recep...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $10.0 million
June 07, 2023
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Recipient : NRx Pharmaceuticals
Deal Size : $345.0 million
Deal Type : Collaboration
Lead Product(s) : Tadalafil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Eli Lilly
Deal Size : $57.5 million
Deal Type : Acquisition
Lotus Acquires Cialis® (Tadalafil) in Taiwan From Lilly
Details : Cialis® (tadalafil), is indicated for the treatment of erectile dysfunction and benign prostatic hyperplasia, and Cialis® is positioned as the top 2 brand product for erectile dysfunction treatment with high brand loyalty.
Product Name : Cialis
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 22, 2022
Lead Product(s) : Tadalafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Eli Lilly
Deal Size : $57.5 million
Deal Type : Acquisition
Reset All
